^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TR1801-ADC

    i
    Other names: TR1801-ADC, MT-8633
    Company:
    Mitsubishi Tanabe, Open Innovation Partners
    Drug class:
    DNA replication inhibitor, c-MET-targeted antibody-drug conjugate
    Related drugs:
    1year
    TR1801-ADC in Patients With Tumors That Express c-Met (clinicaltrials.gov)
    P1, N=15, Suspended, Open Innovation Partners, Inc. | N=40 --> 15 | Trial completion date: Mar 2023 --> Dec 2023 | Active, not recruiting --> Suspended | Trial primary completion date: Mar 2023 --> Jul 2023
    Enrollment change • Trial completion date • Trial suspension • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    TR1801-ADC
    2years
    TR1801-ADC in Patients With Tumors That Express c-Met (clinicaltrials.gov)
    P1, N=40, Recruiting, Tanabe Research Laboratories USA Inc | Active, not recruiting --> Recruiting
    Enrollment open
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    TR1801-ADC
    3years
    TR1801-ADC in Patients With Tumors That Express c-Met (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Tanabe Research Laboratories USA Inc | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    TR1801-ADC
    almost4years
    A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. (PubMed, Clin Cancer Res)
    Together these results suggest the promise of agents such as TR1801-ADC as a novel approach to the treatment of pancreatic cancer.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    gemcitabine • TR1801-ADC